Drug Profile
Batoprotafib - Novartis
Alternative Names: TNO-155Latest Information Update: 12 Mar 2024
Price :
$50
*
At a glance
- Originator Novartis
- Developer Mirati Therapeutics; Novartis
- Class Antineoplastics
- Mechanism of Action Protein tyrosine phosphatase non receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Solid tumours
- No development reported Colorectal cancer
Most Recent Events
- 29 Feb 2024 Novartis withdraws a phase-I pharmacokinetic trial in Hepatic impairment (PO) prior to enrolment (NCT05490030)
- 29 Feb 2024 Novartis withdraws a phase-I pharmacokinetic trial in Renal impairment (PO) prior to enrolment (NCT05541159)
- 23 Jan 2024 Mirati Therapeutics has been acquired by Bristol-Myers Squibb